SCHEMBL4174601

SCHEMBL4174601

Cc1nc2c(-c3cc(N4CCOCC4)ccc3F)cnn2c(N)c1-c1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.48
MEN1 O00255 8/20 0.48
KMT2A Q03164 8/20 0.48
CASP3 P42574 2/20 0.46
SENP8 Q96LD8 2/20 0.46
SENP7 Q9BQF6 2/20 0.46
SENP6 Q9GZR1 2/20 0.46
BLM P54132 1/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
NPC1 O15118 9/20 0.46
KDM4E B2RXH2 2/20 0.42
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LCK P06239 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
AKT1 P31749 1/20 0.38
CNR2 P34972 1/20 0.38
ERAP1 Q9NZ08 1/20 0.38
CAMK2D Q13557 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178621 0.94 RAB9A (0.47) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4172785 0.90 LCK (0.50) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4185185 0.89 NPC1 (0.52) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4180644 0.89 NPC1 (0.47) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4170134 0.89 RAB9A (0.47) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4171682 0.88 MEN1 (0.46) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4184964 0.88 MEN1 (0.46) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4184709 0.87 MEN1 (0.45) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4170123 0.86 RAB9A (0.46) RAB9AMEN1KMT2ACASP3SENP8
SCHEMBL4176946 0.86 MEN1 (0.44) RAB9AMEN1KMT2ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 US disclosed
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 US disclosed
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders EPHA5, EPHA7, EPHA1 RAB9A 849/4885MEN1 4377/4885KMT2A 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.